It was found that polymorphisms in IL13 (a result of the TH2 pathway) modify the association between hormone replacement therapy and the risk for B cell lymphoma, particularly for follicular lymphoma (reduced risk for IL13 GG, CG, genotypes OR 0.4, 95% CI 0.2–0.9, and increased risk for IL13 AG/AA, CT/TT genotypes OR 2.6, 95% CI 1.2–5.5). This evidence concerns the gene IL13 and B-cell non-Hodgkin lymphoma.